Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

U.S. Chamber: Thailand AIDS Drug Decision Sends "Negative Signal"

December 1, 2006

The U.S. Chamber of Commerce today criticized Thailand's decision to break the patent of Merck's antiretroviral treatment efavirenz. The chamber's Bangkok branch warned, "Surprise actions such as these send a negative signal to foreign investors in Thailand regarding transparency and support for intellectual property rights."

The Public Health Ministry's move, announced Wednesday, will allow the Government Pharmaceutical Organization to manufacture the drug generically. GPO already makes nevirapine generically, but thousands of HIV patients have developed resistance to it. The ministry contends many of these drug-resistant patients will die without access to a cheaper version of efavirenz, and the government cannot afford to import enough of the patented product.

While acknowledging Thailand's right to use a compulsory license to get the drug at a lower price, the U.S. Chamber complained that the government took the step without first consulting Merck and seeking a mutual solution.

Advertisement
"We hope that surprise actions such as compulsory licensing do not deter Thailand's important efforts to continue to protect intellectual property and promote a positive investment environment," said Judy Benn, executive director of the chamber's office in Bangkok.

Back to other news for December 1, 2006

Adapted from:
Deutsche Presse-Agentur
12.01.2006


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement